Fig. 2: HFn-encapsulated Dox superiorly killed GC-PDX tumors. | Cell Death & Disease

Fig. 2: HFn-encapsulated Dox superiorly killed GC-PDX tumors.

From: TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer

Fig. 2

a H&E staining showed the similar histology of the patients and their corresponding PDX-derived tumors. b Tumor growth curves for different mouse groups were indicated. Red arrows: dose injection for every 5 days. c Mouse survival curves in different groups with Kaplan–Meier analysis. d Body weight changes in GC-PDX model. Red arrows: dose injection every 5 days. e Detection of proliferative and apoptotic cells in different groups after drug treatment. Scale bars, (e left two panels) 100 µm; (e right panel) 50 µm.

Back to article page